Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Macugen U.S. Sales Could Reach Over $200 Mil. In “Choppy” 2006, OSI Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Launch of Genentech’s pending macular degeneration competitor Lucentis and off-label use of Avastin are factors in Macugen sales projection.

You may also be interested in...



Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition

Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.

Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition

Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.

Macugen Labeling Adds Precaution On Angioedema

Pfizer/OSI’s age-related macular degeneration product now advises consideration of a patient’s medical history for hypersensitivity reactions.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel